Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference

LUND, Sweden, March 6, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that Søren Tulstrup, President and CEO of Hansa Biopharma, will present at the Cowen 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 9:20AM ET/ 3:20PM CET. The conference will be held at the Boston Marriott Copley Place in Boston, MA.

A live webcast will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on March 6, 2019.

For further information, please contact:

Company:

Emanuel Björne
Vice President Business Development and Investor Relations
Hansa Biopharma AB (publ)
Mobile: +46-707-175477
E-mail: emanuel.bjorne@hansabiopharma.com

Swedish Investor and Media Relations:

Cord Communications

Mikael Widell
+46-70-311-99-60
U.K. Investor and Media Relations
FTI Consulting

Simon Conway/ Stephanie Cuthbert
+44 (0)20-3727-1000

U.S. Investor and Media Relations:

Argot Partners

Stephanie Marks / David Rosen (media)
+1-212-600-1902

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-present-at-the-cowen-39th-annual-health-care-conference,c2757210

The following files are available for download:


     
     
     https://mb.cision.com/Main/1219/2757210/1002709.pdf Hansa Biopharma to Present at
                                                               the Cowen 39th Annual Health
                                                               Care Conference

View original content:http://www.prnewswire.com/news-releases/hansa-biopharma-to-present-at-the-cowen-39th-annual-health-care-conference-300807520.html

SOURCE Hansa Biopharma AB